超分割放疗同步化疗治疗Ⅲ期非小细胞肺癌  

The clinical comparative study on hydroxycomptothecin combined with cocurrent hyperfractionated radiotherapy for unresectable stage Ⅲ non-small cell lung cancer

作　　者：李国忠[1] 张绍华[1] 张志[1] 宋文广[1] 王瑞林[1] 付占昭 

机构地区：[1]河北医科大学附属唐山临床医学院放化疗科,唐山063000 [2]秦皇岛人民医院肿瘤科,秦皇岛066000

出　　处：《肿瘤》2008年第2期156-158,共3页Tumor

基　　金：河北省科技攻关项目(编号:052761861)

摘　　要：目的：探讨羟基喜树碱同步超分割放射治疗Ⅲ期不能手术的非小细胞肺癌（non-small cell lung cancer,NSCLC）的疗效、毒副反应和长期疗效。方法：共入选60例患者,分为实验组和对照组,各30例。实验组化疗采用羟基喜树碱10mg/d,于放疗开始和结束的前5d应用,放射治疗为超分割方法,1.2Gy/次,2次/d,总剂量（total dose,Dt）为62.4～67.2Gy;对照组只行超分割放射治疗,方法和剂量完全同实验组。用Kaplan-Meier方法预测长期生存率。结果：共58例患者完成随访,随访率为96%。实验组和对照组的有效率分别为80.0%和66.7%,P〉0.05;2组患者血液学和非血液学的毒副反应比较,P〉0.05;经Kaplan-Meier生存分析,实验组和对照组的1、3年预期生存率分别为77.7%、26.1%和70.3%、15.1%,P〉0.05。结论：羟基喜树碱同步超分割放射治疗Ⅲ期不能手术的NSCLC疗效肯定,与单纯超分割相比较,有一定的增益,但无统计学意义,毒副反应可以耐受。Objective：To investigate the efficacy, toxicity and long-term outcome of hydroxycomptothecin （HCPT） combined concurrent hyperfractionated radiotherapy for unresectable stage Ⅲ non-small cell lung cancer （NSCLC）. Methods：Sixty patients were enrolled into this study and divied into experimental group （n=30） and control group （n=30）. The patients in the experimental group were administered HCPT at 10 mg/d in NS 250 mL （iv, daily） on the first 5 days and the last 5 days during radiotherapy. The patients were given concurrent hyperfractionated radiotherapy at 1.2 Gy, twice daily. The total dosage of radiation was 62.4-67.2 Gy. Patients in the control group only received hyperfractionated radiotherapy. The long-term survival rate was estimated by Kaplan-Meier survival curve. Results：Fifty-eight patients finished the trial. The follow-up rate was 96%. The response rate was 80% in the experimental group and 66.7% in the control group, respectively （P〉0.05）. There was no significant difference in hematologic and non hematolo-gic toxicities between the two groups （P〉0.05）. The predicted 1-and 3-year survival rates were 77.7% and 26.1% for the experimental group and 70.3% and 15.1% for the control group, respectively. There was no significant difference between two groups （P〉0.05）. Conclusion：HCPT combined concurrent hyperfractionated radiotherapy has definite effects on unresectable stage Ⅲ NSCLC. The efficacy of combined therapy is better than hyperfractionated radiotherapy,and but the difference was not significant. The toxicity could be torerated.

关 键 词：癌 非小细胞肺 放射疗法 药物疗法 联合 喜树碱 

分 类 号：R734.2[医药卫生—肿瘤]